Posaconazole CAS No:171228-49-2 Posaconazole is a type of oral triazole antifungal API that has shown a high rate of efficacy for a number of fungal conditions without the risk of severe side effects. While many antifungal medications have ostensibly similar jobs, each one has their own limitations and patient disadvantages. Posaconazole was developed as an[…]
Spotlight on Posaconazole: A Leading Antifungal Medication
Anti-Fungal Tags: Amphotericin BAntifungalfungusPosaconazole Mar 20, 2018
Erlanger, KY / Boca Raton, FL – LGM Pharma LLC today completed the acquisition of Zeta Pharmaceuticals’ compounding business. In Q4 2017, LGM received a significant growth capital investment from private equity firm, New Harbor Capital in Chicago. The acquisition of Zeta’s compounding business is a part of LGM’s strategy to invest in expanding its[…]
3 of the Newest API’s in the Dermatological Antifungal Segment
Anti-Fungal, EU Approved 2014, FDA Approved 2016 Tags: CrisaboroledermatitiseczemaEfinaconazolefungal infectionsPsoriasisTavaborole Jan 16, 2018
The dermatological antifungal segment has three more FDA approved options. This is good news for a specialty area that could use more diversity when it comes to treating fungal infections. Tavaborole and Efinaconazole were both approved by the FDA in 2014 to treat fungi of the nail and nailbeds, and Crisaborole was approved in 2016[…]
LGM Pharma Exhibits at the 2017 AAPS Annual Meeting and Exposition
LGM Pharma, Trade Shows & Events Tags: AAPScontract researchdevelopment & manufacturing organizationsnovel drug delivery Dec 06, 2017
The 2017 AAPS Annual Meeting and Exposition took place in San Diego November 12-15. It brought together more than 6,100 scientists, business leaders, government officials, and students from around the world to share and learn the latest scientific advances and industry developments. The meeting featured 100 scientific sessions and 2,200 posters, workshops, and short courses.[…]
New Harbor Capital Acquires Majority Interest in LGM Pharma
LGM Pharma, Press Release Tags: Gideon SchurderMendy SchurderNew Harbor Capital Nov 21, 2017
Chicago-based private equity firm New Harbor Capital completed a majority equity investment in LGM Pharma, an innovation-driven company involved in distribution of cGMP active pharmaceutical ingredients (“API”) and other value-added services supporting leading pharmaceutical companies. LGM specializes in streamlining the API supply chain throughout all development stages while providing complete technical capabilities and expert regulatory[…]
Andrew Mitrani Appointed as LGM Pharma’s New Associate Director of Business Development
LGM Pharma, Press Release Tags: Andrew Mitrani Nov 06, 2017
NASHVILLE, Tennessee – LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Nashville, Tennessee with administrative offices in Boca Raton, Florida, recently announced that Mr. Andrew Mitrani would be joining the organization as the Associate Director of Business Development. In that capacity, Mr. Andrew Mitrani will be responsible for growing out the business[…]
Chemical entities SHINE in the top 10 fastest-growing drugs of 2016
Anti-Retroviral / Anti-HIV, Blood Product, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014, FDA Approved 2015 Tags: GileadPfizer May 26, 2017
This week, PharmaCompass continued its analysis of the top 10 fastest-growing drugs of 2016 by sales to evaluate the drugs that registered large sales growth. Please note that these are not the top-selling drugs, but are the top 10 drugs that registered the maximum growth in global sales over 2015. Interestingly, things didn’t appear that[…]
LGM Pharma hosted an exclusive CPhI Comedy Night in the Good Good Comedy Theatre in Downtown Philly. The event featured a live comedy show, and plenty of food and drinks for current and prospective clients who were in town for CPhI. CPhI is the world’s leading pharmaceutical platform that brings together pharma ingredients manufacturers, suppliers[…]
2017 CPhI North America – Exhibitor Showcase Sponsors
LGM Pharma, Press Release, Trade Shows & Events May 19, 2017
2017 CPhI North America assembled leading pharmaceutical professionals to provide a forum for solving some of the pharmaceutical industry’s most pressing challenges. One of the highlights of the 2017 CPhI North America conference was LGM Pharma’s presentation at the Exhibitor Showcase. The presenter was LGM Pharma’s Commercial Director, Gideon Schurder. He gave an in-depth look[…]
Brexpiprazole: A Molecule That Should Be On Your Radar
Antidepressant, Antipsychotic Tags: BrexpiprazoleSchizophrenia Mar 27, 2017
Brexpiprazole is a drug used to either treat Schizophrenia or to prevent its relapse. It is also approved for use as an adjuvant in the treatment of Major Depressive Disorder (MDD), as an add-on when first line antidepressants fail to provide sufficient clinical results. Brexpiprazole has been launched under the brand name Rexulti. Brexpiprazole was[…]